Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PRO-140 (Progenics).

G Poli1

  • 1Istituto Scientifico H San Raffaele, DiBit, via Olgettina 58, Milano 20132, Italy. polig@dibit.hsr.it

Idrugs : the Investigational Drugs Journal
|June 21, 2005
PubMed
Summary
This summary is machine-generated.

PRO-140, an antibody targeting CCR5, shows potent in vitro blockade of HIV isolates. This investigational therapy for HIV infection is advancing toward clinical trials, offering potential for reduced side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of industrial processing and storage procedures on oxysterols in milk and milk products.

Food & function·2021
Same author

A short-term study of the effects of ozone irrigation in an orthodontic population with fixed appliances.

European journal of paediatric dentistry·2019
Same author

Increased production of 27-hydroxycholesterol in human colorectal cancer advanced stage: Possible contribution to cancer cell survival and infiltration.

Free radical biology & medicine·2019
Same author

Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis.

Journal of endocrinological investigation·2017
Same author

Hemophilia and nonprogressing human immunodeficiency virus type 1 infection.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Identification of the putative binding pocket of valerenic acid on GABAA receptors using docking studies and site-directed mutagenesis.

British journal of pharmacology·2015
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • PRO-140 is a monoclonal antibody targeting the CCR5 coreceptor.
  • CCR5 is crucial for HIV entry into host cells.
  • Distinct binding sites on CCR5 may allow for targeted HIV therapeutics.

Purpose of the Study:

  • To investigate PRO-140 as a potential treatment for HIV infection.
  • To evaluate the efficacy and safety of PRO-140.
  • To explore novel HIV vaccine strategies based on CCR5.

Main Methods:

  • In vitro studies assessing PRO-140's blockade of primary HIV isolates.
  • Phase I/II clinical trials planned.
  • SBIR grant-funded research in laboratory and animal models.
  • Humanization of PRO-140 by Protein Design Labs.

Related Experiment Videos

Main Results:

  • PRO-140 potently blocked all tested primary HIV isolates utilizing CCR5.
  • The distinct binding site of PRO-140 on CCR5 suggests potential for fewer side effects.
  • Ongoing research to determine breadth, potency, and durability of PRO-140 therapy.

Conclusions:

  • PRO-140 demonstrates significant potential as an anti-HIV therapeutic by blocking CCR5.
  • Further clinical investigation is warranted to confirm safety and efficacy in patients.
  • CCR5-targeted therapies represent a promising avenue for HIV treatment and prevention.